Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 15Triple Negative Breast Neoplasms 5Ovarian Neoplasms 4Prostatic Neoplasms 3Melanoma 3Lymphoma 3Lung Neoplasms 3Endometrial Neoplasms 3Uterine Cervical Neoplasms 2Multiple Myeloma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Leukemia 2Hematologic Neoplasms 2Healthy Participants 2Disease Progression 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Moderate Hepatic Impairment 1

Interventions

capivasertib 2Fulvestrant 2ribociclib 1palbociclib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer × capivasertib × 1 year × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡